MoonLake Immunotherapeutics MLTX Total debt

Total debt at other companies

Eli LillyLLY

$54.91B+37.6%

Oruka Therapeutics, Inc.ORKA

$1.81M+90.8%

Shattuck Labs, Inc.STTK

$2.89M-9.5%

Alumis Inc.ALMS

$35.66M+1,881%

Upstream Bio, Inc.UPB

$1.11M-34.5%

Kymera TherapeuticsKYMR

$80.14M-8.5%

FAQ

What is MoonLake Immunotherapeutics's total debt?

MoonLake Immunotherapeutics (MLTX) reported total debt of $100.8M in Q1 2026.

How has MoonLake Immunotherapeutics's total debt changed year-over-year?

MoonLake Immunotherapeutics's total debt increased by 33.3% year-over-year, from $75.6M to $100.8M.

What is the long-term trend for MoonLake Immunotherapeutics's total debt?

Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's total debt has grown at a 48.8% compound annual growth rate (CAGR), from $15.44M to $75.71M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.